Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Apellis Pharmaceuticals, Inc. ("Apellis") common stock between January 28, 2021 and July 28, 2023, inclusive (the “Class Period”).
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about Apellis’s business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) the design of SYFOVRE’s clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) therefore, Defendants’ statements about Apellis’s business, operations, and prospects lacked a reasonable basis at all relevant times.
Current Status of Case:
On March 17, 2025, the Court granted Defendants Motion to Dismiss. Lead Plaintiff filed a Notice of Appeal on April 16, 2025. The appeal is ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.